Post-renal transplantation hypophosphatemia

Abstract

An understanding of the pathophysiologic mechanisms of post-renal transplant (PRT) bone disease is of important clinical significance. Although bone disease occurs after all solid organ transplantation, the cumulative skeletal fracture rate remains high in PRT subjects while reaching a plateau with other transplantations. One major difference in the pathophysiology of PRT bone disease is, perhaps, due to persistent renal phosphorus (Pi) wasting. Novel phosphaturic agents have recently been suggested to participate in the development of bone disease in PRT subjects. However, it is unclear as of yet whether these factors alone or in conjunction with excess parathyroid hormone (PTH) secretion play a key role in the development of negative Pi balance and consequent bone disease in this population. In this review, I present a natural history of PRT hypophosphatemia and persistent renal Pi leak, provide pathophysiologic insight into these developments, and discuss the difficulty in diagnosing these phenotypes in both adult and pediatric populations.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Papalois VE, Najarian JS (2001) Pediatric kidney transplantation: historic hallmarks and a personal perspective. Pediatr Transplant 5:239–245

    CAS  PubMed  Google Scholar 

  2. 2.

    Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K (1978) Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2:1323–1327

    CAS  PubMed  Google Scholar 

  3. 3.

    Goldstein G, Kremer AB, Barnes L, Hirsch RL (1987) OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients. J Pediatr 111:1046–1050

    CAS  PubMed  Google Scholar 

  4. 4.

    Jensen CW, Jordan ML, Schneck FX, Shapiro R, Tzakis A, Hakala TR, Starzl TE (1991) Pediatric renal transplantation under FK 506 immunosuppression. Transplant Proc 23:3075–3077

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338:161–165

    CAS  PubMed  Google Scholar 

  6. 6.

    Saland JM (2004) Osseous complications of pediatric transplantation. Pediatr Transplant 8:400–415

    PubMed  Google Scholar 

  7. 7.

    Sanchez CP, Salusky IB, Kuizon BD, Ramirez JA, Gales B, Ettenger RB, Goodman WG (1998) Bone disease in children and adolescents undergoing successful renal transplantation. Kidney Int 53:1358–1364

    CAS  Google Scholar 

  8. 8.

    Smets YF, van der Pijl JW, de Fijter JW, Ringers J, Lemkes HH, Hamdy NA (1998) Low bone mass and high incidence of fractures after successful simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 13:1250–1255

    CAS  PubMed  Google Scholar 

  9. 9.

    Vautour LM, Melton LJ 3rd, Clarke BL, Achenbach SJ, Oberg AL, McCarthy JT (2004) Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int 15:160–167

    PubMed  Google Scholar 

  10. 10.

    Ghanekar H, Welch BJ, Moe OW, Sakhaee K (2006) Post-renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens 15:97–104

    CAS  PubMed  Google Scholar 

  11. 11.

    Epstein S (1996) Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 11:1–7

    CAS  PubMed  Google Scholar 

  12. 12.

    Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274–282

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Vega D, Sakhaee K (2007) Osteoporosis following solid organ transplantation. Future Rheumatol 2:341–345

    Google Scholar 

  14. 14.

    Shane E, Rivas M, Staron RB, Silverberg SJ, Seibel MJ, Kuiper J, Mancini D, Addesso V, Michler RE, Factor-Litvak P (1996) Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab 81:1740–1746

    CAS  PubMed  Google Scholar 

  15. 15.

    Ninkovic M, Skingle SJ, Bearcroft PW, Bishop N, Alexander GJ, Compston JE (2000) Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 12:931–935

    CAS  PubMed  Google Scholar 

  16. 16.

    Takeda E, Taketani Y, Sawada N, Sato T, Yamamoto H (2004) The regulation and function of phosphate in the human body. Biofactors 21:345–355

    CAS  PubMed  Google Scholar 

  17. 17.

    Levi M, Kempson SA, Lotscher M, Biber J, Murer H (1996) Molecular regulation of renal phosphate transport. J Membr Biol 154:1–9

    CAS  PubMed  Google Scholar 

  18. 18.

    Biber J, Custer M, Werner A, Kaissling B, Murer H (1993) Localization of NaPi-1, a Na/Pi cotransporter, in rabbit kidney proximal tubules. II. Localization by immunohistochemistry. Pflugers Arch 424:210–215

    CAS  PubMed  Google Scholar 

  19. 19.

    Custer M, Lotscher M, Biber J, Murer H, Kaissling B (1994) Expression of Na-P(I) cotransport in rat kidney: localization by RT-PCR and immunohistochemistry. Am J Physiol 266:F767–F774

    CAS  PubMed  Google Scholar 

  20. 20.

    Segawa H, Kaneko I, Takahashi A, Kuwahata M, Ito M, Ohkido I, Tatsumi S, Miyamoto K (2002) Growth-related renal type II Na/Pi cotransporter. J Biol Chem 277:19665–19672

    CAS  PubMed  Google Scholar 

  21. 21.

    Hilfiker H, Hattenhauer O, Traebert M, Forster I, Murer H, Biber J (1998) Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci USA 95:14564–14569

    CAS  PubMed  Google Scholar 

  22. 22.

    Murer H, Hernando N, Forster I, Biber J (2000) Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 80:1373–1409

    CAS  PubMed  Google Scholar 

  23. 23.

    Tenenhouse HS (2007) Phosphate transport: molecular basis, regulation and pathophysiology. J Steroid Biochem Mol Biol 103:572–577

    CAS  PubMed  Google Scholar 

  24. 24.

    Berndt TJ, Schiavi S, Kumar R (2005) "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289:F1170–F1182

    CAS  PubMed  Google Scholar 

  25. 25.

    Yan X, Yokote H, Jing X, Yao L, Sawada T, Zhang Y, Liang S, Sakaguchi K (2005) Fibroblast growth factor 23 reduces expression of type IIa Na+/Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells. Genes Cells 10:489–502

    CAS  PubMed  Google Scholar 

  26. 26.

    Levi M, Shayman JA, Abe A, Gross SK, McCluer RH, Biber J, Murer H, Lötscher M, Cronin RE (1995) Dexamethasone modulates rat renal brush border membrane phosphate transporter mRNA and protein abundance and glycosphingolipid composition. J Clin Invest 96:207–216

    CAS  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Alcalde AI, Sarasa M, Raldua D, Aramayona J, Morales R, Biber J, Murer H, Levi M, Sorribas V (1999) Role of thyroid hormone in regulation of renal phosphate transport in young and aged rats. Endocrinology 140:1544–1551

    CAS  PubMed  Google Scholar 

  28. 28.

    Ambuhl PM, Meier D, Wolf B, Dydak U, Boesiger P, Binswanger U (1999) Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 34:875–883

    CAS  PubMed  Google Scholar 

  29. 29.

    Levi M (2001) Post-transplant hypophosphatemia. Kidney Int 59:2377–2387

    CAS  PubMed  Google Scholar 

  30. 30.

    Felsenfeld AJ, Gutman RA, Drezner M, Llach F (1986) Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1, 25-dihydroxycholecalciferol. Miner Electrolyte Metab 12:333–341

    CAS  PubMed  Google Scholar 

  31. 31.

    Portale AA, Halloran BP, Morris RC Jr (1989) Physiologic regulation of the serum concentration of 1, 25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 83:1494–1499

    CAS  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Green J, Debby H, Lederer E, Levi M, Zajicek HK, Bick T (2001) Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int 60:1182–1196

    CAS  PubMed  Google Scholar 

  33. 33.

    Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, Weaver C (2000) Peak bone mass. Osteoporos Int 11:985–1009

    CAS  PubMed  Google Scholar 

  34. 34.

    Garabedian M, Silve C, Levy D, Bourdeau A, Ulmann A, Broyer M, Balsan S (1980) Chronic hypophosphatemia in kidney transplanted children and young adults. Adv Exp Med Biol 128:249–254

    CAS  PubMed  Google Scholar 

  35. 35.

    Brodehl J, Krause A, Hoyer PF (1988) Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol 2:183–189

    CAS  PubMed  Google Scholar 

  36. 36.

    Bernheim J, Touraine JL, David L, Faivre JM, Traeger J (1976) Evolution of secondary hyperparathyroidism after renal transplantation. Nephron 16:381–387

    CAS  PubMed  Google Scholar 

  37. 37.

    Claesson K, Hellman P, Frodin L, Rastad J (1998) Prospective study of calcium homeostasis after renal transplantation. World J Surg 22:635–641, discussion 41-2

    CAS  PubMed  Google Scholar 

  38. 38.

    Rosenbaum RW, Hruska KA, Korkor A, Anderson C, Slatopolsky E (1981) Decreased phosphate reabsorption after renal transplantation: Evidence for a mechanism independent of calcium and parathyroid hormone. Kidney Int 19:568–578

    CAS  PubMed  Google Scholar 

  39. 39.

    Salusky IB, Coburn JW, Brill J, Foley J, Slatopolsky E, Fine RN, Goodman WG (1988) Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33:975–982

    CAS  Google Scholar 

  40. 40.

    Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG (1994) Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253–258

    CAS  PubMed  Google Scholar 

  41. 41.

    Graf H, Kovarik J, Stummvoll HK, Wolf A, Pinggera WF (1979) Handling of phosphate by the transplanted kidney. Proc Eur Dial Transplant Assoc 16:624–629

    CAS  PubMed  Google Scholar 

  42. 42.

    Parfitt AM, Kleerekoper M, Cruz C (1986) Reduced phosphate reabsorption unrelated to parathyroid hormone after renal transplantation: implications for the pathogenesis of hyperparathyroidism in chronic renal failure. Miner Electrolyte Metab 12:356–362

    CAS  PubMed  Google Scholar 

  43. 43.

    White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Jüppner H, Econs MJ (2001) The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497–500

    CAS  PubMed  Google Scholar 

  44. 44.

    Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663

    CAS  PubMed  Google Scholar 

  45. 45.

    White KE, Evans WE, O’Riordan J, Speer MC, Econs MJ, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348

    CAS  Google Scholar 

  46. 46.

    Riancho JA, de Francisco AL, del Arco C, Amado JA, Cotorruelo JG, Arias M, Gonzalez-Macias J (1988) Serum levels of 1, 25-dihydroxyvitamin D after renal transplantation. Miner Electrolyte Metab 14:332–337

    CAS  Google Scholar 

  47. 47.

    Steiner RW, Ziegler M, Halasz NA, Catherwood BD, Manolagas S, Deftos LJ (1993) Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1–25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients. Transplantation 56:843–846

    CAS  PubMed  Google Scholar 

  48. 48.

    Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Jüppner H, Wolf M (2006) Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'? Kidney Int 70:1486–1494

    CAS  Google Scholar 

  49. 49.

    Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y (2004) FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65:1943–1946

    CAS  Google Scholar 

  50. 50.

    Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, White KE (2005) Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146:4647–4656

    CAS  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Imel EA, Econs MJ (2005) Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol 16:2565–2575

    CAS  PubMed  Google Scholar 

  52. 52.

    Itoh N, Ornitz DM (2004) Evolution of the Fgf and Fgfr gene families. Trends Genet 20:563–569

    CAS  PubMed  Google Scholar 

  53. 53.

    Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770–774

    CAS  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120–6123

    CAS  PubMed  PubMed Central  Google Scholar 

  55. 55.

    Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD (2008) FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 19:2342–2350

    CAS  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Baum M, Syal A, Quigley R, Seikaly M (2006) Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia. Pediatr Nephrol 21:1067–1074

    PubMed  Google Scholar 

  57. 57.

    Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N (2008) Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 23:939–948

    CAS  PubMed  Google Scholar 

  58. 58.

    Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435

    CAS  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT (2004) FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89:4489–4492

    CAS  PubMed  Google Scholar 

  60. 60.

    Ferrari SL, Bonjour JP, Rizzoli R (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519–1524

    CAS  PubMed  Google Scholar 

  61. 61.

    Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272–2279

    CAS  PubMed  Google Scholar 

  62. 62.

    Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M (2004) Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250–256

    CAS  PubMed  Google Scholar 

  63. 63.

    Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M (2004) Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44:481–487

    CAS  PubMed  Google Scholar 

  64. 64.

    Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205–2215

    CAS  PubMed  Google Scholar 

  65. 65.

    Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Jüppner H, Salusky IB (2009) Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94:511–517

    CAS  Google Scholar 

  66. 66.

    Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, Schiavi SC, Slatapolsky E, Brown AJ (2006) FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 104:p23–32

    CAS  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y (2007) Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18:2683–2688

    CAS  PubMed  Google Scholar 

  68. 68.

    Liu S, Tang W, Zhou J, Vierthaler L, Quarles LD (2007) Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 293:E1636–E1644

    CAS  PubMed  Google Scholar 

  69. 69.

    Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM, Kronenberg HM, Baron R, Schipani E (2001) Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 107:277–286

    CAS  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, Kumar R (2003) Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112:785–794

    CAS  PubMed  PubMed Central  Google Scholar 

  71. 71.

    Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL (2000) MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67:54–68

    CAS  PubMed  Google Scholar 

  72. 72.

    Liang CT, Barnes J, Balakir R, Cheng L, Sacktor B (1982) In vitro stimulation of phosphate uptake in isolated chick renal cells by 1, 25-dihydroxycholecalciferol. Proc Natl Acad Sci USA 79:3532–3536

    CAS  PubMed  Google Scholar 

  73. 73.

    Kurnik BR, Hruska KA (1984) Effects of 1, 25-dihydroxycholecalciferol on phosphate transport in vitamin D-deprived rats. Am J Physiol 247:F177–F184

    CAS  PubMed  Google Scholar 

  74. 74.

    Loffing J, Lotscher M, Kaissling B, Biber J, Murer H, Seikaly M, Alpern RJ, Levi M, Baum M, Moe OW (1998) Renal Na/H exchanger NHE-3 and Na-PO4 cotransporter NaPi-2 protein expression in glucocorticoid excess and deficient states. J Am Soc Nephrol 9:1560–1567

    CAS  PubMed  PubMed Central  Google Scholar 

  75. 75.

    Falkiewicz K, Nahaczewska W, Boratynska M, Owczarek H, Klinger M, Kaminska D, Wozniak M, Szepietowski T, Patrzalek D (2003) Tacrolimus decreases tubular phosphate wasting in renal allograft recipients. Transplant Proc 35:2213–2215

    CAS  PubMed  Google Scholar 

  76. 76.

    Maalouf NM, Shane E (2005) Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 90:2456–2465

    CAS  PubMed  Google Scholar 

  77. 77.

    Feller RB, McDonald JA, Sherbon KJ, McCaughan GW (1999) Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg 5:407–413

    CAS  PubMed  Google Scholar 

  78. 78.

    Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D (1996) Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 28:105–114

    CAS  PubMed  Google Scholar 

  79. 79.

    Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH (2000) High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11:1093–1099

    CAS  PubMed  Google Scholar 

  80. 80.

    Carlini RG, Rojas E, Weisinger JR, Lopez M, Martinis R, Arminio A, Bellorin-Font E (2000) Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 36:160–166

    CAS  PubMed  Google Scholar 

  81. 81.

    Burckhardt P, Michel C (1989) The peak bone mass concept. Clin Rheumatol 8[Suppl 2]:16–21

    PubMed  Google Scholar 

  82. 82.

    Seeman E (2003) Bone quality. Osteoporos Int 14[Suppl 5]:S3–7

    PubMed  Google Scholar 

Download references

Acknowledgements

The author would like to acknowledge Ms. Hadley Armstrong for her primary role in the preparation and editorial review of this manuscript.

Disclosures

The author has nothing to disclose.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Khashayar Sakhaee.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sakhaee, K. Post-renal transplantation hypophosphatemia. Pediatr Nephrol 25, 213–220 (2010). https://doi.org/10.1007/s00467-009-1252-4

Download citation

Keywords

  • Bone disease
  • Hypophosphatemia
  • Phosphorus wasting
  • Post-renal transplantation